Prospective external validation of an updated algorithm to quantify risk of febrile neutropenia in cancer patients after a cycle of chemotherapy

Basit Öğe Kaydı
dc.contributor.authorBozcuk, Hakan
dc.contributor.authorCoskun, Hasan Senol
dc.contributor.authorIlhan, Yusuf
dc.contributor.authorGoksu, Sema Sezgin
dc.contributor.authorYildiz, Mustafa
dc.contributor.authorBayram, Selami
dc.contributor.authorYerlikaya, Tahir
dc.date.accessioned2024-02-23T13:55:50Z
dc.date.available2024-02-23T13:55:50Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractPurpose Febrile neutropenia resulting from chemotherapy is a significant cause of morbidity and mortality in cancer patients. We had previously published the associates of the risk of febrile neutropenia, and this study now extends and modifies the previous model as well as tests its external validity. Methods We have recruited documented febrile neutropenia cases with solid tumors, in addition to a selected control group of cancer patients from one institution treated between 2015 and 2019. We then united our sample with our previously published original derivation group, to modify and update our previous model by logistic regression analysis. Additionally, consecutive cancer patients from 5 institutions were recruited in 2020 to test external validity of the resultant algorithm. Results A total of 4075 cycles of chemotherapy in 1282 cases were recruited in the updated, new model derivation group, and a total of 8 variables were selected for the updated algorithm. In the new external validation group, 653 cycles of chemotherapy in 624 patients were analyzed, to indicate that after cycles without prophylactic granulocyte colony-stimulating factor (GCSF) usage, the algorithm yielded a sensitivity value of 91%, specificity of 40%, and an area under curve (AUC) figure of 0.78, when a risk cutoff threshold value of >= 0.20 is chosen. This algorithm is now embedded in a web application for free clinical use. Conclusion Our algorithm identifies and quantifies the risk of febrile neutropenia in cancer patients. Further studies are required to improve this model with additional predictors.en_US
dc.identifier.doi10.1007/s00520-021-06681-0
dc.identifier.endpage2629en_US
dc.identifier.issn0941-4355
dc.identifier.issn1433-7339
dc.identifier.issue3en_US
dc.identifier.pmid34816328en_US
dc.identifier.scopus2-s2.0-85119831455en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2621en_US
dc.identifier.urihttps://doi.org/10.1007/s00520-021-06681-0
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10972
dc.identifier.volume30en_US
dc.identifier.wosWOS:000721667800003en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofSupportive Care In Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFebrile Neutropeniaen_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.subjectLogistic Regression Analysisen_US
dc.titleProspective external validation of an updated algorithm to quantify risk of febrile neutropenia in cancer patients after a cycle of chemotherapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu